Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKinsey
Merck
Harvard Business School
McKesson

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 10,189,903

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,189,903
Title:Bispecific chimeric antigen receptors and methods of use thereof to treat cancer
Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
Inventor(s): Jensen; Michael (Bainbridge, WA)
Assignee: Seattle Children\'s Hospital (Seattle, WA)
Application Number:15/233,140
Patent Claims:see list of patent claims

Details for Patent 10,189,903

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Try it Free 2032-02-13
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2032-02-13
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2032-02-13
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Try it Free 2032-02-13
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Try it Free 2032-02-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Colorcon
Mallinckrodt
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.